Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABS-LT: Long-Term Safety of Ambrisentan in Pulmonary Hypertension
NCT00777920Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2008
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of ambrisentan in pulmonary hypertension (PH), sponsored by Gilead Sciences. Started Nov 2008; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00777920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777920.